Illumina Inc (NASDAQ:ILMN)
| 137.27 Delayed Data As of Sep 29 |  +4.92 / +3.72%Today’s Change | 127.37 Today|||52-Week Range 248.87 | -32.11% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $21.7B |
Company Description
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Contact Information
Illumina, Inc. 5200 Illumina Way San Diego California 92122 |
Employees
Shareholders
| Individual stakeholders | 6.04% |
| Mutual fund holders | 55.77% |
| Other institutional | 39.10% |
Top Executives
| Jacob Thaysen | Chief Executive Officer |
| Kevin Pegels | Chief-Global Operations |
| Joydeep Goswami | CFO, Chief Strategy & Development Officer |
| Steven Barnard | Chief Technology Officer |
| Carissa Rollins | Chief Information Officer |
